ABBV vs GS: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and The Goldman Sachs Group, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
The Goldman Sachs Group, Inc. · Financial Services
$926.55
-45.0% upside to fair value
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(+6.3%).
GS trades at a lower forward P/E
(15.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
GS |
| Current Price |
$197.69 |
$926.55 |
| Fair Value Estimate |
$210.22 |
$509.60 |
| Upside to Fair Value |
+6.3%
|
-45.0%
|
| Market Cap |
$349.7B |
$275.0B |
| Forward P/E |
83.3x
|
15.6x
|
| EV / EBITDA |
23.4x
|
30.6x
|
| Price / Sales |
5.7x
|
2.5x
|
| Price / FCF |
18.7x
|
-5.8x
|
| Revenue Growth YoY |
+10.0%
|
-45.4%
|
| Gross Margin |
70.2%
|
55.5%
|
| Operating Margin |
26.7%
|
20.5%
|
| Return on Equity |
-361.6%
|
14.6%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
—
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
The Goldman Sachs Group, Inc. operates as a leading global financial services firm specializing in investment banking, securities, investment management, and consumer banking. The company benefits from a high-quality business model characterized by strong brand recognition, deep client relationships, and a history of stable leadership. However, the stock is currently significantly overvalued, tra…
Accumulation Zones
| Metric |
ABBV |
GS |
| Zone Low |
$157.66 |
$382.20 |
| Zone High |
$178.69 |
$433.16 |
| In Buy Zone? |
No
|
No
|